

MSS2024

HYBRID

Next Generation Lipid Nanoparticles for RNA Vaccines and Therapeutics

Dan Peer

NeoVac, Oxford, United Kingdom

I will detail the Lipid Nanoparticles (LNPs) 2.0 platform for cell specific delivery of RNA payloads. I will show vaccine applications in infectious diseases (e.g. COVID) as well as the first bacterial mRNA vaccine. In addition, I will detail the ability of our platform to entrap very large payloads including for DMD and multiple transcripts of mRNA for cancer therapeutics.

 PORTOROZ, SLOVENIA

 3-7 June 2024